🇺🇸 FDA
Patent

US 7214690

Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods

granted A61PA61P13/08A61P15/08

Quick answer

US patent 7214690 (Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods) held by Ligand Pharmaceuticals Incorporated expires Mon May 03 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue May 08 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 03 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
58
CPC classes
A61P, A61P13/08, A61P15/08, A61P15/10, A61P17/00